GET DAILY SIGNALSEditas Medicine (EDIT): Is the $6.60 Analyst Target With +154% Upside Within Reach?
Key Takeaways
- The central stock price target of $6.60 is the arithmetic mean of eight verified analyst price targets, rounded to the nearest clean figure; the underlying calculated mean is approximately $6.63.
- Analyst price targets range widely, from $4.00 to $15.00, reflecting substantial disagreement about EDIT-401's clinical and commercial prospects.
- With the stock recently around $2.60, reaching $6.60 would require upside of roughly 154%, a very large move for any equity.
- The strongest supporting factor is the progress of EDIT-401 toward first-in-human studies, including regulatory clearance for a Phase 1/2 trial and a cash runway extending into the third quarter of 2027.
- The biggest risks include early-stage clinical execution, no approved products or predictable revenue, competition in gene editing, and the possibility of future equity dilution.
- For deeper context, you can review this ticker's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
- For a broader view of AI-driven market tools, explore Trending AI Robots.
Analyst Price Targets and Consensus View
Eight current, attributable analyst targets were reviewed to calculate the central target. The individual targets and firms are: Evercore ISI at $15 (Outperform, reiterated May 2026); JonesTrading at $8 (Buy, maintained August 2026); Ladenburg Thalmann at $6 (Buy, initiated August 2026); Wells Fargo at $6 (Overweight, upgraded October 2026); Guggenheim at $5 (Buy, upgraded September 2026); H.C. Wainwright at $5 (Buy, reiterated August 2026); RBC Capital at $4 (Hold, maintained August 2026); and Chardan Capital at $4 (Buy, May 2026).
The resulting mean is about $6.63, which rounds to the $6.60 central target. The approximate low-to-high range is $4.00 to $15.00, an unusually wide spread. Bullish analysts argue that EDIT-401's strong preclinical LDL-C reductions in non-human primates support meaningful clinical potential, with Evercore ISI's $15 target reflecting a far more aggressive view of the program's value. More cautious analysts, such as RBC Capital's Hold with a $4 target, emphasize the early stage of the pipeline and limited visibility. Bank of America Securities maintains a Sell rating without a published target, underscoring that not every firm shares the constructive stance. I also checked this using Tickeron’s AI Daily Buy/Sell Signals to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
With EDIT recently trading around $2.60, reaching $6.60 would require roughly 154% appreciation, a very large move. The stock has traded between a 52-week low near $1.66 and a high near $4.28, so the central target sits far above the stock's recent peak.
Editas Medicine has no approved products; its revenue comes primarily from collaboration and licensing agreements, including a Cas9 license to Vertex Pharmaceuticals. The company reported full-year 2025 revenue of about $40.5 million and posted a narrower-than-expected quarterly loss in mid-2026. The path to a higher valuation rests almost entirely on the clinical de-risking of EDIT-401, rather than near-term earnings or profitability.
What Could Support a Move Toward the Target
The principal catalyst is EDIT-401's advancement. Editas received clearance to initiate a first-in-human Phase 1/2 trial for EDIT-401 in HeFH in October 2026, and the company has guided toward early human proof-of-concept data. Analysts such as H.C. Wainwright and TD Cowen have cited the program's preclinical data showing substantial, durable LDL-C reductions as supportive of the translational hypothesis.
Management has also emphasized a cash runway extending into the third quarter of 2027, which analysts view as sufficient to fund the IND (investigational new drug) submission, trial initiation, and initial human data readout without immediate financing pressure. A favorable data readout, a partnership, or positive regulatory milestones could re-rate the shares meaningfully.
What Could Prevent the Target From Being Reached
The risks are substantial. EDIT-401 is unproven in humans, and gene editing carries safety, efficacy, and regulatory uncertainties that could delay or derail development. Editas has a history of pipeline pivots, including the discontinuation of reni-cel, which previously pressured the shares. The company remains unprofitable and is expected to continue generating net losses, creating ongoing dilution risk even with the current cash runway.
Competition in both in vivo gene editing and the broader cardiovascular market is intense, and sentiment toward speculative biotech can shift quickly with broader risk appetite or sector rotation. The very wide analyst range, from $4 to $15, itself signals how uncertain the outcome remains.
Technical Levels and Market Structure
From a technical standpoint, EDIT has recently traded below both its 50-day and 200-day simple moving averages, indicating a downtrend over the medium term. The 52-week range of roughly $1.66 to $4.28 frames the recent market structure, with the $4.00-to-$4.30 area representing a meaningful prior-high zone that the stock would first need to reclaim before the $6.60 target becomes relevant. A sustained move above the 200-day moving average would be a necessary early step in any longer-term trend reversal. From what I see, these levels help frame the risk-reward picture clearly.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of about 12 months, though firms may apply different assumptions. Investors should monitor initial EDIT-401 human data, IND/CTA (clinical trial application) progress and trial enrollment updates, upcoming quarterly earnings and cash-burn commentary, analyst revisions, and any partnership or financing announcements. The next earnings report is expected in November 2026.
Using AI Daily Buy/Sell Signals in Practice
In my research process, Tickeron's AI Daily Buy/Sell Signals has been a useful addition for tracking names like this one. The system continuously monitors thousands of stocks and ETFs to generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. It helps me discover opportunities, monitor existing positions, and spot emerging trend shifts more efficiently than manual screening alone, providing an extra data-driven layer alongside fundamental work on volatile biotech names.
Final Assessment
The $6.60 central target, derived from the mean of eight analyst price targets, implies roughly 154% upside from a recent price near $2.60, a very large move that would require successful clinical de-risking of EDIT-401. Supporting the case are the program's encouraging preclinical data, first-in-human trial clearance, and a cash runway into 2027. Weighing against it are the absence of approved products, persistent losses and dilution risk, intense competition, and a wide analyst range from $4 to $15 that reflects genuine uncertainty. Reaching $6.60 is not a near-term expectation but a high-upside, high-risk scenario hinging primarily on clinical data and execution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
EDIT in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 14, 2026
EDIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 37 of 43 cases where EDIT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +9.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 179 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In 74 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 42 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
EDIT moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for EDIT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.793) is normal, around the industry mean (3.037). P/E Ratio (-3.939) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which translates genome editing technology into a novel class of human therapeutics
Industry Biotechnology
Advertisement